Abstract: Age-related macular degeneration(AMD) is the main disease in today's world of the elderly blind, often resulting in severe vision loss, due to wet AMD in macular choroidal neovascularization (CNV) for clinical characteristics. Vascular endothelial growth factor (VEGF) is known as one of the factors promoting neovascularization stimulated the main form. But VEGF inhibitors by antagonism. Inhibition of angiogenesis, reduce blood capillary permeability, promoting CNV exudate absorption. Although there are Bevacizumab off label use problem, it is still relatively good shortterm therapeutic effect and low treatment cost in the international community has been widely used in the field of ophthalmology. The scheme of intravitreal injection Bevacizumab (125 mg) once a month, continuous 3 times is better than the scheme after once injection, then according to the disease situation for again injection. After intravitreal injection Bevacizumab, both fundus anatomical structure and visual acuity were improved in patients with wet AMD.  (Int Rev Ophthalmol, 2014, 38:   351-355)